Abbott Labs PT receives Investment Bank Analyst Rating Update
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Wednesday, July 20th. Please refresh for updates. Netflix (NASDAQ:NFLX) stock rose 6.6% after the streaming...
Abbott (ABT) reported Q2 EPS of $1.43, $0.30 better than the analyst estimate of $1.13. Revenue for the quarter came in at $11.3 billion versus the consensus estimate of $10.31...
Many growth stocks and exchange-traded funds (ETFs) are currently changing hands around 52-week or even multi-year lows and the impending earnings season could bring more...
The US Federal Reserve has recently delivered its most significant interest rate hike since 1994 to counter four-decade high inflation, pushing the S&P 500 deeper into bear market...
Biotechnology stocks represent companies that research, develop or market healthcare-related therapies or products. They typically use living organisms, biological systems, or...
Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceutical Products segment includes gastroenterology products, women’s health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. Its Nutritional Products segment includes various forms of infant formula and follow-on formula, adult and other pediatric nutritional products and others.
|Average||139.03 (+38.09% Upside)|
|No. of Analysts||16|